By Benjamin Horney ( February 20, 2015, 6:11 PM EST) -- Valeant Pharmaceuticals International Inc. is closing in on a $10.2 billion deal to buy fellow pharmaceutical company Salix Pharmaceuticals Ltd., Reuters reported Friday. According to the report, Valeant's bid would value Salix at about $160 per share, and an announcement could come in the next several days. The news comes just a day after reports had U.K. drugmaker throwing its hat into the ring for Salix....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.